The update was based on data from the phase 3 PSO-LONG trial, a randomized, double-blind, vehicle-controlled study that evaluated the long-term use of Enstilar Foam in 545 adults. The Food and Drug ...

LEO Pharma A/S today announced that new data being presented at the 23 rd World Congress of Dermatology shows aerosol foam Enstilar ® (calcipotriol/betamethasone ...

LEO Pharma has shared positive results from a late-stage trial of Enstilar (LEO 90100) in adults with stable plaque psoriasis. Between 2% and 3% of the global population has some form of psoriasis, a ...

Please provide your email address to receive an email when new articles are posted on . LEO Pharma announced in a press release that Enstilar has received scientific approval in the E.U. for treating ...

LEO Pharma has announced positive data from the Phase III clinical trial of Enstilar (LEO 90100) in Chinese adult patients with stable plaque psoriasis. An aerosol spray foam, enstilar combines ...

LEO Pharma has received scientific approval for Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis vulgaris ...

NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the ...

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar ® has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of plaque ...

The FDA has approved Leo Pharma’s Enstilar foam for the treatment of plaque psoriasis. The approval comes on the back of a clinical trial that showed patients achieved significant degrees of ...

Please provide your email address to receive an email when new articles are posted on . The long-term, vehicle-controlled, double-blind, phase 3 PSO-LONG trial compared twice-weekly Enstilar foam ...

FOR DISTRIBUTION TO UK CONSUMER MEDIA ONLY (EXCLUDING REPUBLIC OF IRELAND AND MEDICAL MEDIA) Adherence is a significant challenge for patients living with psoriasis (studies consistently suggest that ...

The marketing approval of Enstilar(R) would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received ...